Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL)

British Journal of Haematology
Chiara RusconiFondazione Italiana Linfomi (FIL)

Abstract

Optimal treatment for transformed follicular lymphoma (tFL) is not fully defined. Clinical characteristics and treatments that impact on post-transformation outcome of 176 biopsy-proven tFL were analysed. Transformation occurred at initial diagnosis in 52% (Group 1) and after a FL diagnosis in 48% (Group 2). Five-year overall survival was 84% for Group 1 and 51% for Group 2 (P < 0·001). In Group 1, 5-year progression-free survival was superior after rituximab maintenance compared to observation only (94% vs. 53%, P = 0·024). In Group 2, an inverse trend was found between survival and both a higher number of pre-transformation treatment lines and a short time-to-transformation.

References

Oct 18, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hervé GhesquièresGilles Salles
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Oct 12, 2013·British Journal of Haematology·Makiko Ban-HoefenJonathan W Friedberg
Jan 15, 2014·Annals of Hematology·Hany R GuirguisRena Buckstein
Nov 21, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C MadsenF A d'Amore
Dec 8, 2015·Hematology·Silvia Montoto
Aug 11, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Umberto VitoloLaurie H Sehn
Oct 19, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L MagnanoA López-Guillermo
Aug 7, 2018·The Lancet. Haematology·Massimo FedericoUNKNOWN Aristotle Consortium
Nov 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L MagnanoA López-Guillermo

❮ Previous
Next ❯

Citations

Dec 10, 2019·American Journal of Hematology·Arnold Freedman, Eric Jacobsen
Jul 31, 2020·Leukemia & Lymphoma·Clémentine Sarkozy, David W Scott
Feb 23, 2021·Drugs·Michael Northend, William Townsend
Aug 26, 2021·Hematological Oncology·Hanae IdaTakahiro Fukuda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

© 2022 Meta ULC. All rights reserved